Protective effect of high density lipoprotein associated paraoxonase. Inhibition of the biological activity of minimally oxidized low density lipoprotein.

Our group has previously demonstrated that oxidized phospholipids in mildly oxidized LDL (MM-LDL) produced by oxidation with lipoxygenase, iron, or cocultures of artery wall cells increase monocyte-endothelial interactions and this sequence of events is blocked by HDL. To obtain further insight into the mechanism by which HDL abolishes the activity of MM-LDL we investigated the effect of the HDL-associated ester hydrolase paraoxonase (PON). Treatment of MM-LDL with purified PON significantly reduced the ability of MM-LDL to induce monocyte-endothelial interactions. Inactivation of PON by pretreating HDL with heat or EDTA reduced the ability of HDL to inhibit LDL modification. HPLC analysis of phospholipids isolated from MM-LDL before and after treatment with purified PON showed that the 270 nm absorbance of phospholipids was decreased, while no effect was observed on 235 nm absorbance. Oxidized 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphorylcholine (Ox-PAPC) and specific fractions of Ox-PAPC isolated by HPLC induced the same monocyte-endothelial interactions as did MM-LDL. Biologically active and inactive HPLC fractions of Ox-PAPC were compared by fast atom bombardment-mass spectrometry which revealed that active fractions possessed ions with a mass to charge [correction of change] ratio greater than native PAPC by multiples of 16 D suggesting the addition of 3 and 4 oxygen atoms to PAPC. Comparison of Ox-PAPC by fast atom bombardment-mass spectrometry before and after PON treatment showed that PON destroyed these multi-oxygenated molecules found in biologically active fractions of Ox-PAPC. These results suggest that PON in HDL may protect against the induction of inflammatory responses in artery wall cells by destroying biologically active lipids in mildly oxidized LDL.

[1]  J. Berliner,et al.  Effect of platelet activating factor-acetylhydrolase on the formation and action of minimally oxidized low density lipoprotein. , 1995, The Journal of clinical investigation.

[2]  M. Kendall,et al.  The oxidation hypothesis of atherosclerosis , 1994, The Lancet.

[3]  E. Änggård,et al.  Formation of F2‐isoprostanes during aortic endothelial cell‐mediated oxidation of low density lipoprotein , 1994, FEBS letters.

[4]  F. Pagani,et al.  The protective role of high-density lipoprotein on oxidized-low-density-lipoprotein-induced U937/endothelial cell interactions. , 1994, European journal of biochemistry.

[5]  J. Berliner,et al.  The role of oxidized low-density lipoprotein in atherogenesis , 1993 .

[6]  K. Badr,et al.  Vascular smooth muscle actions and receptor interactions of 8-iso-prostaglandin E2, an E2-isoprostane. , 1993, Biochemical and biophysical research communications.

[7]  F. Parhami,et al.  Minimally modified low density lipoprotein-induced inflammatory responses in endothelial cells are mediated by cyclic adenosine monophosphate. , 1993, The Journal of clinical investigation.

[8]  V. Simeon,et al.  Heat inactivation of paraoxonase and arylesterase activities in human and rabbit serum. , 1993, Chemico-biological interactions.

[9]  D. Steinberg,et al.  Role of oxidized low density lipoprotein in atherogenesis. , 1991, The Journal of clinical investigation.

[10]  J. Morrow,et al.  Effects of a novel prostaglandin, 8-epi-PGF2 alpha, in rabbit lung in situ. , 1992, The American journal of physiology.

[11]  G. Zimmerman,et al.  The platelet-activating factor acetylhydrolase from human plasma prevents oxidative modification of low-density lipoprotein. , 1992, Transactions of the Association of American Physicians.

[12]  A. J. Valente,et al.  Monocyte transmigration induced by modification of low density lipoprotein in cocultures of human aortic wall cells is due to induction of monocyte chemotactic protein 1 synthesis and is abolished by high density lipoprotein. , 1991, The Journal of clinical investigation.

[13]  S. Ratnam,et al.  Influence of serum paraoxonase polymorphism on serum lipids and apolipoproteins , 1991, Clinical genetics.

[14]  P. Durrington,et al.  Paraoxonase prevents accumulation of lipoperoxides in low‐density lipoprotein , 1991, FEBS letters.

[15]  D. Stafforini,et al.  Human plasma platelet-activating factor acetylhydrolase. Oxidatively fragmented phospholipids as substrates. , 1991, The Journal of biological chemistry.

[16]  G. Chisolm,et al.  Lipoxygenase-mediated transformation of human low density lipoprotein to an oxidized and cytotoxic complex. , 1991, Journal of lipid research.

[17]  A. Smolen,et al.  Purification of human serum paraoxonase/arylesterase. Evidence for one esterase catalyzing both activities. , 1991, Drug metabolism and disposition: the biological fate of chemicals.

[18]  D. Steinberg,et al.  Role of oxidised low density lipoprotein in atherogenesis. , 1993, British heart journal.

[19]  A. J. Valente,et al.  Minimally modified low density lipoprotein induces monocyte chemotactic protein 1 in human endothelial cells and smooth muscle cells. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[20]  L. Fong,et al.  High-density lipoprotein inhibits the oxidative modification of low-density lipoprotein. , 1990, Biochimica et biophysica acta.

[21]  M. Territo,et al.  Minimally modified low density lipoprotein stimulates monocyte endothelial interactions. , 1990, The Journal of clinical investigation.

[22]  A. Lusis,et al.  Induction of endothelial cell expression of granulocyte and macrophage colony-stimulating factors by modified low-density lipoproteins , 1990, Nature.

[23]  J. Goldstein,et al.  Scavenging for receptors , 1990, Nature.

[24]  A. Gotlieb,et al.  Macrovascular Endothelial Cells from Porcine Aorta , 1990 .

[25]  D. Stafforini,et al.  Platelet-activating factor acetylhydrolase from human plasma. , 1990, Methods in enzymology.

[26]  J L Witztum,et al.  Evidence for the presence of oxidatively modified low density lipoprotein in atherosclerotic lesions of rabbit and man. , 1989, The Journal of clinical investigation.

[27]  J L Witztum,et al.  Beyond cholesterol. Modifications of low-density lipoprotein that increase its atherogenicity. , 1989, The New England journal of medicine.

[28]  G. Zimmerman,et al.  An oxidized derivative of phosphatidylcholine is a substrate for the platelet-activating factor acetylhydrolase from human plasma. , 1989, The Journal of biological chemistry.

[29]  D. Morel,et al.  Superoxide anion participation in human monocyte-mediated oxidation of low-density lipoprotein and conversion of low-density lipoprotein to a cytotoxin. , 1989, Journal of immunology.

[30]  J L Witztum,et al.  Low density lipoprotein undergoes oxidative modification in vivo. , 1989, Proceedings of the National Academy of Sciences of the United States of America.

[31]  D. Gordon,et al.  High-density lipoprotein cholesterol and cardiovascular disease. Four prospective American studies. , 1989, Circulation.

[32]  L. Stevenson,et al.  Monocyte migration into the subendothelial space of a coculture of adult human aortic endothelial and smooth muscle cells. , 1988, The Journal of clinical investigation.

[33]  M. Territo,et al.  Modification of the Recalde method for the isolation of human monocytes. , 1988, Journal of lipid research.

[34]  M. Haberland,et al.  Malondialdehyde-altered protein occurs in atheroma of Watanabe heritable hyperlipidemic rabbits. , 1988, Science.

[35]  C. Walker,et al.  Low A-esterase activity in serum of patients with fish-eye disease. , 1987, Clinical chemistry.

[36]  D. Steinberg,et al.  Macrophage Oxidation of Low Density Lipoprotein Generates a Modified Form Recognized by the Scavenger Receptor , 1986, Arteriosclerosis.

[37]  D. Epps,et al.  Rapid separation of lipid classes in high yield and purity using bonded phase columns. , 1985, Journal of lipid research.

[38]  D. Steinberg,et al.  Enhanced Macrophage Degradation of Biologically Modified Low Density Lipoprotein , 1983, Arteriosclerosis.

[39]  J. Chemnitius,et al.  Organophosphate detoxicating hydrolases in different vertebrate species. , 1983, Comparative biochemistry and physiology. C, Comparative pharmacology and toxicology.

[40]  G. Chisolm,et al.  LDL-induced cytotoxicity and its inhibition by HDL in human vascular smooth muscle and endothelial cells in culture. , 1979, Atherosclerosis.

[41]  M C Hjortland,et al.  High density lipoprotein as a protective factor against coronary heart disease. The Framingham Study. , 1977, The American journal of medicine.

[42]  W. J. Dyer,et al.  A rapid method of total lipid extraction and purification. , 1959, Canadian journal of biochemistry and physiology.

[43]  R. Havel,et al.  The distribution and chemical composition of ultracentrifugally separated lipoproteins in human serum. , 1955, The Journal of clinical investigation.

[44]  O. H. Lowry,et al.  Protein measurement with the Folin phenol reagent. , 1951, The Journal of biological chemistry.